YOSEMITE and RHINE
Purpose: Faricimab is a novel anti–angiopoietin-2 and anti–vascular endothelial growth factor (VEGF) bispecific antibody with high affinities and specificities for both VEGF and angiopoietin-2. It is postulated that targeting angiogenic factors and inflammatory pathways in addition to the VEGF pathw...
Main Authors: | Nicole Eter, MD, PhD, Rishi P. Singh, MD, Francis Abreu, PhD, Kemal Asik, PhD, Karen Basu, PhD, Caroline Baumal, MD, Andrew Chang, PhD, Karl G. Csaky, MD, Zdenka Haskova, MD, PhD, Hugh Lin, MD, Carlos Quezada Ruiz, MD, Paisan Ruamviboonsuk, MD, David Silverman, MSc, MRCOphth, Charles C. Wykoff, MD, PhD, Jeffrey R. Willis, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-03-01
|
Series: | Ophthalmology Science |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666914521001093 |
Similar Items
-
BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion
by: Lars-Olof Hattenbach, MD, PhD, et al.
Published: (2023-09-01) -
TENAYA and LUCERNE
by: Arshad M. Khanani, MD, MA, et al.
Published: (2021-12-01) -
Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
by: Yusuke Kikuchi, PhD, et al.
Published: (2024-03-01) -
Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice
by: Robyn Guymer, MBBS, PhD, et al.
Published: (2024-05-01) -
Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report
by: Shetal A. Patel, MD, PhD, et al.
Published: (2024-10-01)